| MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy GW Sledge Jr, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... Journal of clinical oncology 35 (25), 2875-2884, 2017 | 1474 | 2017 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Journal of Clinical Oncology 35 (32), 3638-3646, 2017 | 1459 | 2017 |
| A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival KN Ogston, ID Miller, S Payne, AW Hutcheon, TK Sarkar, I Smith, ... The Breast 12 (5), 320-327, 2003 | 1127 | 2003 |
| Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel IC Smith, SD Heys, AW Hutcheon, ID Miller, S Payne, FJ Gilbert, ... Journal of clinical oncology 20 (6), 1456-1466, 2002 | 1052 | 2002 |
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study PA Jänne, AT Shaw, JR Pereira, G Jeannin, J Vansteenkiste, C Barrios, ... The lancet oncology 14 (1), 38-47, 2013 | 769 | 2013 |
| Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials SD Heys, LG Walker, I Smith, O Eremin Annals of surgery 229 (4), 467-477, 1999 | 761 | 1999 |
| Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE) SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... Journal of Clinical Oncology 38 (34), 3987-3998, 2020 | 599 | 2020 |
| Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy IC Smith, AE Welch, AW Hutcheon, ID Miller, S Payne, F Chilcott, ... Journal of Clinical Oncology 18 (8), 1676-1688, 2000 | 524 | 2000 |
| Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial SD Heys, AW Hutcheon, TK Sarkar, KN Ogston, ID Miller, S Payne, I Smith, ... Clinical breast cancer 3, S69-S74, 2002 | 275 | 2002 |
| Staging of the Axilla in Breast Cancer: Accurate: In Vivo: Assessment Using Positron Emission Tomography With 2-(Fluorine-18)-Fluoro-2-Deoxy-D-Glucose IC Smith, KN Ogston, P Whitford, FW Smith, P Sharp, M Norton, ID Miller, ... Annals of surgery 228 (2), 220-227, 1998 | 176 | 1998 |
| Monitoring primary breast cancer throughout chemotherapy using FDG-PET GM McDermott, A Welch, RT Staff, FJ Gilbert, L Schweiger, SIK Semple, ... Breast cancer research and treatment 102, 75-84, 2007 | 151 | 2007 |
| Nonlocalized postactivation performance enhancement (PAPE) effects in trained athletes: a pilot study F Cuenca-Fernández, IC Smith, MJ Jordan, BR MacIntosh, ... Applied physiology, nutrition, and metabolism 42 (10), 1122-1125, 2017 | 136 | 2017 |
| Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial) DREAMS Trial Collaborators, West Midlands Research Collaborative bmj 357, 2017 | 133 | 2017 |
| Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the … I Smith, M Dowsett Breast Cancer Res Treat 82 (suppl 1), 1a, 2003 | 89 | 2003 |
| Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer PA Jänne, I Smith, G McWalter, H Mann, B Dougherty, J Walker, MCM Orr, ... British journal of cancer 113 (2), 199-203, 2015 | 85 | 2015 |
| monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast … SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... J Clin Oncol 38 (34), 3987-3998, 2020 | 79 | 2020 |
| Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant … PA Janne, AT Shaw, JR Pereira, G Jeannin, J Vansteenkiste, CH Barrios, ... Journal of Clinical Oncology 30 (15_suppl), 7503-7503, 2012 | 60 | 2012 |
| Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine … RD Carvajal, GK Schwartz, H Mann, I Smith, PD Nathan BMC cancer 15, 1-9, 2015 | 56 | 2015 |
| A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies RB Cohen, S Aamdal, M Nyakas, M Cavallin, D Green, M Learoyd, I Smith, ... European journal of cancer 49 (7), 1521-1529, 2013 | 52 | 2013 |
| 40th EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5–9 September 2004 M Veitenhansl, K Stegner, FX Hierl, C Dieterle, H Feldmeier, B Gutt, ... Diabetologia 47, A1-A464, 2004 | 51 | 2004 |
